The FDA this week post­ed an un­ti­tled let­ter sent Oct. 17 to Chi­na-based ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API) ...

GSK is leav­ing the bio­phar­ma trade group BIO, a spokesper­son con­firmed, the lat­est large phar­ma to back out of the ...

Am­gen and As­traZeneca said on Fri­day that their asth­ma drug Tezspire re­duced nasal con­ges­tion and the size of nasal ...

Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most ...

In another sign that biopharma companies are slowing their early R&D efforts, Charles River Laboratories is shuttering more than a dozen sites. The service provider is working on “consolidating ...

Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the ...

Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects ...

Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the ...

Athira Pharma has shelved a daily drug for Alzheimer’s after a mid-stage flop, instead shifting its focus to an oral ...

Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a ...

Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its plans for a ...

The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his ...